18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
A single-center, real world study to evaluate the role of FES-PET in guiding the first-line treatment of HR+/HER2- MBC patients.
Epistemonikos ID: 4040768885c945f18b04c59ccf1307c536622e64
First added on: Oct 24, 2024